Fate Therapeutics (FATE)

2026-07-09T13:15:20.000Z - 12 days ago

Fate Therapeutics announces FDA clearance of FT839 IND application

Jul 9, 2026, 8:30 AM EDT - 12 days ago

Fate Therapeutics Receives FDA Clearance of Investigational New Drug Application for FT839 Product Candidate

Jul 6, 2026, 8:30 AM EDT - 15 days ago

Fate Therapeutics to Present Preliminary Clinical Data of FT819 Off-the-Shelf CAR T-Cell Product Candidate for Systemic Sclerosis at the ISSCR 2026 Annual Meeting

Jul 1, 2026, 4:05 PM EDT - 19 days ago

Fate Therapeutics to Participate in Upcoming Third Quarter 2026 Conferences

Jun 15, 2026, 8:30 AM EDT - 5 weeks ago

Fate Therapeutics Appoints Laura Hamill to Board of Directors

Jun 4, 2026, 8:30 AM EDT - 6 weeks ago

Fate Therapeutics Showcases Data from FT819 and FT839 Programs at the European Congress of Rheumatology Annual Meeting

2026-06-03T20:55:38.000Z - 6 weeks ago

Fate Therapeutics management to meet with Piper Sandler

Jun 3, 2026, 7:00 AM EDT - 6 weeks ago

Fate Therapeutics Slides: Corporate presentation

Jun 2, 2026, 4:05 PM EDT - 6 weeks ago

Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)

Jun 1, 2026, 8:30 AM EDT - 7 weeks ago

Fate Therapeutics Showcases Clinical Data for FT836 at the American Society of Cancer Oncology Annual Meeting

2026-05-22T11:55:08.000Z - 2 months ago

Fate Therapeutics price target raised to $2.20 from $2 at BofA

May 21, 2026, 8:30 AM EDT - 2 months ago

Fate Therapeutics Announces Presentations at 2026 ASCO and EULAR Annual Meetings Highlighting Off-the-Shelf CAR T-cell Therapy Pipeline for Cancer and Autoimmune Diseases

2026-05-19T19:15:09.000Z - 2 months ago

Fate Therapeutics assumed with a Buy at Jefferies

2026-05-13T15:28:57.000Z - 2 months ago

Fate Therapeutics reports Q1 EPS (26c), consensus (28c)

May 13, 2026, 8:30 AM EDT - 2 months ago

Fate Therapeutics Reports First Quarter 2026 Financial Results and Business Updates

May 13, 2026, 8:30 AM EDT - 2 months ago

Fate Therapeutics Earnings release: Q1 2026

May 13, 2026, 8:30 AM EDT - 2 months ago

Fate Therapeutics Quarterly report: Q1 2026

May 11, 2026, 8:30 AM EDT - 2 months ago

Fate Therapeutics Showcases FT819 Clinical Activity in SLE without the use of Conditioning Chemotherapy at the 2026 ASGCT Annual Meeting

May 5, 2026, 8:30 AM EDT - 2 months ago

Fate Therapeutics Selected for U.S. FDA Chemistry, Manufacturing, and Controls Development and Readiness Pilot Program to Support Manufacturing Readiness of FT819

May 4, 2026, 9:00 AM EDT - 2 months ago

Fate Therapeutics Announces Three Presentations at the 2026 ASGCT Annual Meeting Highlighting Off-the-Shelf CAR T-cell Therapy Pipeline for Cancer and Autoimmune Diseases

2026-05-04T10:17:06.000Z - 2 months ago

Fate Therapeutics price target raised to $7 from $5 at H.C. Wainwright

May 1, 2026, 4:05 PM EDT - 2 months ago

Fate Therapeutics Reports New Employee Inducement Award Under Nasdaq Listing Rule 5635(c)(4)

Apr 30, 2026, 9:00 AM EDT - 2 months ago

Fate Therapeutics Announces Data Presentation of FT819 Off-the-Shelf CAR T-Cell Product Candidate for Systemic Lupus Erythematosus (SLE) at the CCR – East 2026 Meeting

SLE

Apr 24, 2026, 8:00 AM EDT - 3 months ago

Fate Therapeutics Proxy statement: Proxy filing

Apr 24, 2026, 8:00 AM EDT - 3 months ago

Fate Therapeutics Proxy statement: Proxy filing

2026-04-16T13:53:30.000Z - 3 months ago

Fate Therapeutics announces data presentation of FT839

Apr 14, 2026, 3:45 PM EDT - 3 months ago

Fate Therapeutics Transcript: 25th Annual Needham Virtual Healthcare Conference

Mar 9, 2026, 9:20 AM EDT - 4 months ago

Fate Therapeutics Transcript: Leerink Global Healthcare Conference 2026

Mar 3, 2026, 4:05 PM EST - 4 months ago

Fate Therapeutics to Participate in Leerink Partners 2026 Global Healthcare Conference

2026-02-26T14:07:37.000Z - 5 months ago

Fate Therapeutics reports Q4 EPS (77c), consensus (27c)

Feb 26, 2026, 7:00 AM EST - 5 months ago

Fate Therapeutics Earnings release: Q4 2025

Feb 26, 2026, 7:00 AM EST - 5 months ago

Fate Therapeutics Annual report: Q4 2025

Feb 26, 2026, 7:00 AM EST - 5 months ago

Fate Therapeutics Annual report: Q4 2025

Feb 26, 2026, 7:00 AM EST - 5 months ago

Fate Therapeutics Slides: Corporate presentation

Feb 16, 2026, 1:00 PM EST - 5 months ago

IPSC-derived NK Cells Clinical Trial Pipeline Gains Momentum: 12+ Companies Lead the Charge in Pioneering New Treatments | DelveInsight

IPSC

2025-12-08T13:21:05.000Z - 8 months ago

Fate Therapeutics presents updated Phase 1 data of FT819

Dec 2, 2025, 9:00 AM EST - 8 months ago

Fate Therapeutics Transcript: Piper Sandler 37th Annual Healthcare Conference

Nov 25, 2025, 8:00 AM EST - 8 months ago

Fate Therapeutics to Present at Piper Sandler 37th Annual Healthcare Conference

2025-11-13T13:35:50.000Z - 8 months ago

Fate Therapeutics reports Q3 EPS (27c), consensus (28c)

Nov 13, 2025, 8:30 AM EST - 8 months ago

Fate Therapeutics Reports Third Quarter 2025 Financial Results and Business Updates

Nov 13, 2025, 8:30 AM EST - 8 months ago

Fate Therapeutics Earnings release: Q3 2025

Nov 13, 2025, 8:30 AM EST - 8 months ago

Fate Therapeutics Quarterly report: Q3 2025

2025-10-31T10:15:39.000Z - 9 months ago

Fate Therapeutics upgraded to Buy from Neutral at H.C. Wainwright

2025-10-27T13:45:07.000Z - 9 months ago

Wedbush upgrades Fate Therapeutics to Outperform, raises target to $7

2025-10-27T11:05:46.000Z - 9 months ago

Fate Therapeutics upgraded to Outperform from Neutral at Wedbush

Oct 26, 2025, 11:30 AM EDT - 9 months ago

Fate Therapeutics Presents New Clinical Data at ACR Convergence 2025 Demonstrating Immune Remodeling and Durable Responses in Patients with Systemic Lupus Erythematosus Treated with FT819 Off-the-Shelf CAR T-Cell Therapy

2025-10-14T12:15:56.000Z - 10 months ago

Fate Therapeutics appoints Adawi as CFO

Sep 4, 2025, 10:55 AM EDT - 11 months ago

Fate Therapeutics Transcript: Cantor Global Healthcare Conference 2025

2025-08-13T10:20:32.000Z - 1 year ago

Fate Therapeutics price target lowered to $2.50 from $4 at Wells Fargo

2025-08-12T20:17:43.000Z - 1 year ago

Fate Therapeutics reports Q2 EPS (29c), consensus (34c)

Aug 12, 2025, 4:01 PM EDT - 1 year ago

Fate Therapeutics Reports Second Quarter 2025 Financial Results and Business Updates

Aug 12, 2025, 7:00 AM EDT - 1 year ago

Fate Therapeutics Earnings release: Q2 2025

Aug 12, 2025, 7:00 AM EDT - 1 year ago

Fate Therapeutics Quarterly report: Q2 2025

2025-06-11T13:10:38.000Z - 1 year ago

Fate Therapeutics announces updated data for FT819

Jun 11, 2025, 9:00 AM EDT - 1 year ago

Fate Therapeutics Announces Updated Clinical Data for FT819 Off-the-shelf CAR T-cell Product Candidate Demonstrating Durability of Drug-free Remission for Severe Lupus Nephritis at EULAR 2025 Congress

May 30, 2025, 4:30 PM EDT - 1 year ago

Fate Therapeutics Appoints Matthew Abernethy, M.B.A., to its Board of Directors

May 28, 2025, 5:54 PM EDT - 1 year ago

Fate Therapeutics Announces Phase 1 Data Presentation of FT819 Off-the-Shelf CAR T-cell Product Candidate for SLE at EULAR 2025 Congress

2025-05-14T11:19:42.000Z - 1 year ago

Fate Therapeutics price target lowered to $4 from $5 at Baird

2025-05-14T09:51:28.000Z - 1 year ago

Fate Therapeutics price target lowered to $2 from $10 at Barclays

May 13, 2025, 4:01 PM EDT - 1 year ago

Fate Therapeutics Reports First Quarter 2025 Financial Results and Business Updates

May 13, 2025, 4:00 PM EDT - 1 year ago

Fate Therapeutics Quarterly report: Q1 2025

May 13, 2025, 4:00 PM EDT - 1 year ago

Fate Therapeutics Earnings release: Q1 2025

Apr 29, 2025, 9:25 AM EDT - 1 year ago

Fate Therapeutics Announces Five Presentations on Off-the-Shelf CAR T-cell Product Platform at ASGCT Annual Meeting

Apr 17, 2025, 8:00 AM EDT - 1 year ago

Fate Therapeutics Proxy statement: Proxy Filing

Apr 17, 2025, 8:00 AM EDT - 1 year ago

Fate Therapeutics Proxy statement: Proxy Filing

Apr 14, 2025, 8:00 AM EDT - 1 year ago

Fate Therapeutics Receives Regenerative Medicine Advanced Therapy (RMAT) Designation from FDA for FT819 to Treat Moderate to Severe Systemic Lupus Erythematosus (SLE)

Apr 7, 2025, 8:00 AM EDT - 1 year ago

Fate Therapeutics Proxy statement: Proxy Filing

Mar 12, 2025, 11:20 AM EDT - 1 year ago

Fate Therapeutics Transcript: Leerink Global Healthcare Conference 2025

Mar 11, 2025, 8:30 AM EDT - 1 year ago

Fate Therapeutics Transcript: Barclays 27th Annual Global Healthcare Conference

Mar 5, 2025, 4:01 PM EST - 1 year ago

Fate Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Business Updates

Mar 5, 2025, 4:00 PM EST - 1 year ago

Fate Therapeutics Annual report: Q4 2024

Mar 5, 2025, 4:00 PM EST - 1 year ago

Fate Therapeutics Earnings release: Q4 2024

Mar 3, 2025, 11:50 AM EST - 1 year ago

Fate Therapeutics Transcript: TD Cowen 45th Annual Healthcare Conference

Feb 14, 2025, 4:01 PM EST - 1 year ago

Fate Therapeutics to Present at Upcoming Investor Conferences

Feb 7, 2025, 7:00 AM EST - 1 year ago

Fate Therapeutics Slides: Corporate Presentation

Dec 9, 2024, 4:01 PM EST - 1 year ago

Fate Therapeutics Presents New Phase 1 Clinical Data of FT819 Off-the-shelf, CAR T-cell Product Candidate for Systemic Lupus Erythematosus

Dec 4, 2024, 3:00 PM EST - 1 year ago

Fate Therapeutics Transcript: Piper Sandler 36th Annual Healthcare Conference

Dec 3, 2024, 2:30 PM EST - 1 year ago

Fate Therapeutics Transcript: Citi's 2024 Global Healthcare Conference

Nov 29, 2024, 1:05 PM EST - 1 year ago

Fate Therapeutics Announces Leadership Transition

Nov 26, 2024, 4:01 PM EST - 1 year ago

Fate Therapeutics to Present at Upcoming December Investor Conferences

Nov 18, 2024, 8:05 AM EST - 1 year ago

Fate Therapeutics Presents 6-Month Follow-up Data on First Patient Treated in Phase 1 Autoimmunity Study with Fludarabine-free Conditioning and FT819 Off-the-shelf, 1XX CAR T-cell Product Candidate at ACR Convergence

Nov 12, 2024, 4:01 PM EST - 1 year ago

Fate Therapeutics Reports Third Quarter 2024 Financial Results and Business Updates

Nov 12, 2024, 3:00 PM EST - 1 year ago

Fate Therapeutics Quarterly report: Q3 2024

Nov 12, 2024, 3:00 PM EST - 1 year ago

Fate Therapeutics Earnings release: Q3 2024

Nov 9, 2024, 1:30 PM EST - 1 year ago

Fate Therapeutics Highlights Cancer-selective, HER2-Targeting Profile of FT825 / ONO-8250 CAR T-cell Product Candidate for Treatment of Advanced Solid Tumors at 2024 SITC Annual Meeting

Nov 8, 2024, 4:01 PM EST - 1 year ago

Fate Therapeutics Presents Pan-tumor Targeting Preclinical Data for FT836 MICA/B-targeted CAR T-cell Product Candidate at 2024 SITC Annual Meeting

Sep 19, 2024, 12:45 PM EDT - 1 year ago

Fate Therapeutics Transcript: 2024 Cantor Fitzgerald Global Healthcare Conference

Sep 12, 2024, 4:01 PM EDT - 2 years ago

Fate Therapeutics to Present at 2024 Cantor Global Healthcare Conference

Aug 13, 2024, 4:05 PM EDT - 2 years ago

Fate Therapeutics Reports Second Quarter 2024 Financial Results and Business Updates

Aug 13, 2024, 4:00 PM EDT - 2 years ago

Fate Therapeutics Quarterly report: Q2 2024

Aug 13, 2024, 4:00 PM EDT - 2 years ago

Fate Therapeutics Earnings release: Q2 2024

Jun 5, 2024, 3:00 PM EDT - 2 years ago

Fate Therapeutics Transcript: Jefferies 2024 Global Healthcare Conference

May 29, 2024, 4:01 PM EDT - 2 years ago

Fate Therapeutics to Present at 2024 Jefferies Global Healthcare Conference

May 9, 2024, 5:00 PM EDT - 2 years ago

Fate Therapeutics Earnings Call Transcript: Q1 2024

May 9, 2024, 5:00 PM EDT - 2 years ago

Fate Therapeutics Quarterly report: Q1 2024

May 9, 2024, 5:00 PM EDT - 2 years ago

Fate Therapeutics Earnings release: Q1 2024

May 9, 2024, 4:01 PM EDT - 2 years ago

Fate Therapeutics Reports First Quarter 2024 Financial Results and Business Updates

May 9, 2024, 8:30 AM EDT - 2 years ago

Fate Therapeutics Announces First Lupus Patient Treated in Phase 1 Autoimmunity Study of Off-the-shelf FT819 CAR T-cell Program

May 3, 2024, 4:30 PM EDT - 2 years ago

Fate Therapeutics Announces Presentation of FT522 Preclinical Data for Autoimmune Diseases in Late-breaking Abstract at ASGCT Annual Meeting

Apr 26, 2024, 8:00 AM EDT - 2 years ago

Fate Therapeutics Proxy statement: Proxy Filing

Apr 26, 2024, 8:00 AM EDT - 2 years ago

Fate Therapeutics Proxy statement: Proxy Filing

Apr 22, 2024, 4:30 PM EDT - 2 years ago

Fate Therapeutics Announces Presentation of FT819 Proof-of-Concept Data for B cell-mediated Autoimmune Diseases at ASGCT Annual Meeting

Apr 18, 2024, 8:00 AM EDT - 2 years ago

Fate Therapeutics Registration statement: Registration Filing

Apr 16, 2024, 8:00 AM EDT - 2 years ago

Fate Therapeutics Proxy statement: Proxy Filing

Apr 10, 2024, 2:15 PM EDT - 2 years ago

Fate Therapeutics Transcript: 23rd Annual Needham Virtual Healthcare Conference

Mar 26, 2024, 3:00 PM EDT - 2 years ago

Fate Therapeutics Transcript: H.C. Wainwright 2ND Annual Cell Therapy Virtual Conference

Mar 19, 2024, 8:44 AM EDT - 2 years ago

Fate Therapeutics Announces Pricing of $100 Million Underwritten Offering and Concurrent Private Placement

Mar 12, 2024, 11:15 AM EDT - 2 years ago

Fate Therapeutics Transcript: Barclays 26th Annual Global Healthcare Conference 2024

Mar 11, 2024, 2:00 PM EDT - 2 years ago

Fate Therapeutics Transcript: Leerink Partners Global Biopharma Conference 2024

Mar 6, 2024, 9:10 AM EST - 2 years ago

Fate Therapeutics Transcript: TD Cowen 44th Annual Health Care Conference 2024

Mar 1, 2024, 8:00 AM EST - 2 years ago

Fate Therapeutics to Present at Upcoming March Investor Conferences

Feb 26, 2024, 5:00 PM EST - 2 years ago

Fate Therapeutics Earnings Call Transcript: Q4 2023

Feb 26, 2024, 5:00 PM EST - 2 years ago

Fate Therapeutics Annual report: Q4 2023

Feb 26, 2024, 5:00 PM EST - 2 years ago

Fate Therapeutics Earnings release: Q4 2023

Feb 26, 2024, 4:01 PM EST - 2 years ago

Fate Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Business Updates

Feb 15, 2024, 8:00 AM EST - 2 years ago

Fate Therapeutics to Webcast Conference Call Reporting Fourth Quarter and Full Year 2023 Financial Results

Dec 13, 2023, 5:00 PM EST - 2 years ago

Fate Therapeutics Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Nov 9, 2023, 8:00 PM EST - 2 years ago

Fate Therapeutics Slides: Corporate Presentation

Nov 8, 2023, 5:00 PM EST - 2 years ago

Fate Therapeutics Earnings Call Transcript: Q3 2023

Nov 8, 2023, 5:00 PM EST - 2 years ago

Fate Therapeutics Quarterly report: Q3 2023

Nov 8, 2023, 5:00 PM EST - 2 years ago

Fate Therapeutics Earnings release: Q3 2023

Nov 8, 2023, 4:01 PM EST - 2 years ago

Fate Therapeutics Reports Third Quarter 2023 Financial Results and Business Updates

Nov 8, 2023, 7:00 AM EST - 2 years ago

Fate Therapeutics Registration statement: Registration Filing

Oct 25, 2023, 8:00 AM EDT - 2 years ago

Fate Therapeutics to Webcast Conference Call Reporting Third Quarter 2023 Financial Results